The Korea Bio Association announced on the 28th that its affiliated organization, the Genomic Company Council, elected Shin Dong-jik, CEO of Medizen Humancare, as the new chairman. His term will be for two years, starting on the 1st of next month.
The vice chairman elected was Kwon Soon-jae, CEO of Acurgen. The operating committee includes Kim Chang-hoon, CEO of Macrogen, Hwang Tae-soon, CEO of Theragen Health, and Ryu Jae-hak, CEO of Lab Genomics.
Chairman Shin Dong-jik said, "In a situation where more corporations are facing crises due to changes in the internal and external environments, we will expand membership and strengthen solidarity among corporations internally, and promote government relations externally to drive industrial development."
The Genomic Company Council was launched in 2015 as a corporate council for research on the authorization of genomic analysis services, regulatory responses, and policy improvements.